THE FIRST AND ONLY APPROVED

IMMUNOTHERAPY TO IMPROVE OS AND PFS IN STAGE III NSCLC

FOLLOWING CRT IN UNRESECTABLE PATIENTS WITH PD-L1 ≥1%1

Enable the immune system

RECOGNISE. RESPOND.2

img-1
img-1

IMFINZI helps restore the anti-tumour immune response2

img-2
img-2

Learn more about PD-L1 testing for The PACIFIC Regimen

img-3
img-3

View the safety and tolerability profile for IMFINZI

THERAPEUTIC INDICATIONS 

IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.

CRT: chemoradiation therapy; NSCLC: non-small cell lung cancer; OS: overall survival; PD-L1: programmed cell death ligand-1; PFS: progression-free survival

References: 1. IMFINZI - UK Summary of Product Characteristics. Date: February 2021 2. Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052-1062.